文献速递冠心病血脂与心血管预防

稳定性缺血性心脏病常规血运重建与初始药物治疗的系统评价与荟萃分析

Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials.
PubMed 文献 · Circulation · 2020-06-26

结果显示常规血运重建未降低死亡风险(RR 0.99, 95%CI 0.90-1.09),但降低非手术性心肌梗死和不稳定型心绞痛风险并提高无 angina 生存率,代价是增加手术性心肌梗死。

要点

  • 常规血运重建未显著降低稳定性缺血性心脏病患者死亡风险。
  • 血运重建降低非手术性心肌梗死(RR 0.76)和不稳定型心绞痛(RR 0.64)风险。
  • 血运重建增加手术性心肌梗死风险(RR 2.48),但总体心肌梗死无差异。

核心结论

  • 在稳定性缺血性心脏病患者中,常规血运重建未改善生存率,但降低非手术性心肌梗死和不稳定型心绞痛风险并提高无 angina 生存率,代价是增加手术性心肌梗死。

研究设计与样本

  • 系统评价与荟萃分析,检索 PUBMED/EMBASE/Cochrane Central Register of Controlled Trials 的随机试验。

主要发现

  • 常规血运重建与药物治疗相比,死亡风险无显著降低(RR 0.99, 95%CI 0.90-1.09)。
  • 试验序贯分析显示累计 z 曲线跨过无效边界,表明缺乏10%或以上死亡风险降低的明确证据。
  • 血运重建降低非手术性心肌梗死风险(RR 0.76, 95%CI 0.67-0.85),但增加手术性心肌梗死风险(RR 2.48, 95%CI 1.86-3.31),总体心肌梗死无差异(RR 0.93, 95%CI 0.83-1.03)。
  • 血运重建降低不稳定型心绞痛风险(RR 0.64, 95%CI 0.45-0.92)并提高无 angina 生存率(RR 1.10, 95%CI 1.05-1.15)。
  • 心力衰竭或卒中风险无治疗相关差异。

临床怎么用

  • 对于稳定性缺血性心脏病患者,常规血运重建不应仅以降低死亡风险为目的,需综合评估症状及缺血负荷。
  • 血运重建可考虑用于缓解心绞痛症状及降低非手术性心肌梗死风险,但需权衡手术性心肌梗死风险。

局限性

  • 大多数试验纳入左心室收缩功能保留且症状负担低的患者,并排除左主干病变患者。
  • 需要更长期随访以评估非致命性自发事件减少是否改善长期生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Revascularization is often performed in patients with stable ischemic heart disease. However, whether revascularization reduces death and other cardiovascular outcomes is uncertain. METHODS: We conducted PUBMED/EMBASE/Cochrane Central Register of Controlled Trials searches for randomized trials comparing routine revascularization versus an initial conservative strategy in patients with stable ischemic heart disease. The primary outcome was death. Secondary outcomes were cardiovascular death, myocardial infarction (MI), heart failure, stroke, unstable angina, and freedom from angina. Trials were stratified by percent stent use and by percent statin use to evaluate outcomes in contemporary trials. RESULTS: Fourteen randomized clinical trials that enrolled 14 877 patients followed up for a weighted mean of 4.5 years with 64 678 patient-years of follow-up fulfilled our inclusion criteria. Most trials enrolled patients with preserved left ventricular systolic function and low symptom burden, and excluded patients with left main disease. Revascularization compared with medical therapy alone was not associated with a reduced risk of death (relative risk [RR], 0.99 [95% CI, 0.90-1.09]). Trial sequential analysis showed that the cumulative z-curve crossed the futility boundary, indicating firm evidence for lack of a 10% or greater reduction in death. Revascularization was associated with a reduced nonprocedural MI (RR, 0.76 [95% CI, 0.67-0.85]) but also with increased procedural MI (RR, 2.48 [95% CI, 1.86-3.31]) with no difference in overall MI (RR, 0.93 [95% CI, 0.83-1.03]). A significant reduction in unstable angina (RR, 0.64 [95% CI, 0.45-0.92]) and increase in freedom from angina (RR, 1.10 [95% CI, 1.05-1.15]) was also observed with revascularization. There were no treatment-related differences in the risk of heart failure or stroke. CONCLUSIONS: In patients with stable ischemic heart disease, routine revascularization was not associated with improved survival but was associated with a lower risk of nonprocedural MI and unstable angina with greater freedom from angina at the expense of higher rates of procedural MI. Longer-term follow-up of trials is needed to assess whether reduction in these nonfatal spontaneous events improves long-term survival.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bangalore S, Maron DJ, Stone GW, et al. Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trials. Circulation. 2020. PMID: 32794407. doi:10.1161/CIRCULATIONAHA.120.048194

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。